Evidence map›Paper›PMID 35847383›Full record

ArticleF1000Research2021

A roadmap for the generation of benchmarking resources for antimicrobial resistance detection using next generation sequencing.

Mauro Petrillo, Marco Fabbri, Dafni Maria Kagkli, Maddalena Querci, Guy Van den Eede, Erik Alm, Derya Aytan-Aktug, Salvador Capella-Gutierrez, Catherine Carrillo, Alessandro Cestaro and 21 more

Abstract read
In one paragraph

Article in F1000Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Mauro Petrillo *European Commission Joint Research Centre, Ispra, Italy.ORCID 0000-0002-6782-4704
Marco Fabbri *European Commission Joint Research Centre, Ispra, Italy.
Dafni Maria Kagkli *European Commission Joint Research Centre, Ispra, Italy.
Maddalena QuerciEuropean Commission Joint Research Centre, Ispra, Italy.ORCID 0000-0002-0788-1627
Guy Van den EedeEuropean Commission Joint Research Centre, Ispra, Italy.
Erik AlmThe European Centre for Disease Prevention and Control, Stockholm, Sweden.
Derya Aytan-AktugNational Food Institute, Technical University of Denmark, Lyngby, Denmark.
Salvador Capella-GutierrezBarcelona Supercomputing Centre (BSC), Barcelona, Spain.ORCID 0000-0002-0309-604X
Catherine CarrilloOttawa Laboratory - Carling, Canadian Food Inspection Agency, Ottawa, Ontario, Canada.ORCID 0000-0002-2334-8718
Alessandro CestaroFondazione Edmund Mach, San Michele all'Adige (TN), Italy.
Kok-Gan ChanInternational Genome Centre, Jiangsu University, Zhenjiang, China.ORCID 0000-0002-1883-1115
Teresa CoqueServicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Christoph EndrullatMSD SHARP & DOHME GMBH, Haar, Germany.ORCID 0000-0001-8646-6589
Ivo GutCentro Nacional de Análisis Genómico, Centre for Genomic Regulation (CNAG-CRG), Barcelona Institute of Technology, Barcelona, Spain.
Paul HammerBIOMES. NGS GmbH c/o Technische Hochschule Wildau, Wildau, Germany.
Gemma L KayQuadram Institute Bioscience, Norwich Research Park, Norwich, UK.ORCID 0000-0002-1176-8459
Jean-Yves MadecUnité Antibiorésistance et Virulence Bactériennes, ANSES Site de Lyon, Lyon, France.
Alison E MatherQuadram Institute Bioscience, Norwich Research Park, Norwich, UK.
Alice Carolyn McHardyHelmholtz Centre for Infection Research, Braunschweig, Germany.
Thierry NaasFrench-NRC for CPEs, Service de Bactériologie-Hygiène, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
Valentina ParacchiniEuropean Commission Joint Research Centre, Ispra, Italy.
Silke PeterInstitute of Medical Microbiology and Hygiene, University of Tübingen, Tübingen, Germany.
Arthur PightlingCenter for Food Safety and Applied Nutrition, US Food and Drug Administration, College Park, MD, USA.
Barbara RaffaelEuropean Commission Joint Research Centre, Ispra, Italy.
John RossenDepartment of Medical Microbiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-7167-8623
Etienne RuppéIAME, Université de Paris, Paris, France.
Robert SchlabergDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.
Kevin VannesteTransversal activities in Applied Genomics, Sciensano, Brussels, Belgium.
Lukas M WeberInstitute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-3282-1730
Henrik WesthHvidovre University Hospital, Hvidovre, Denmark.
Alexandre Angers-Loustau *European Commission Publications Office, Luxembourg, Luxembourg.ORCID 0000-0003-1425-4143

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Next Generation Sequencing technologies significantly impact the field of Antimicrobial Resistance (AMR) detection and monitoring, with immediate uses in diagnosis and risk assessment. For this application and in general, considerable challenges remain in demonstrating sufficient trust to act upon the meaningful information produced from raw data, partly because of the reliance on bioinformatics pipelines, which can produce different results and therefore lead to different interpretations. With the constant evolution of the field, it is difficult to identify, harmonise and recommend specific methods for large-scale implementations over time. In this article, we propose to address this challenge through establishing a transparent, performance-based, evaluation approach to provide flexibility in the bioinformatics tools of choice, while demonstrating proficiency in meeting common performance standards. The approach is two-fold: first, a community-driven effort to establish and maintain "live" (dynamic) benchmarking platforms to provide relevant performance metrics, based on different use-cases, that would evolve together with the AMR field; second, agreed and defined datasets to allow the pipelines' implementation, validation, and quality-control over time. Following previous discussions on the main challenges linked to this approach, we provide concrete recommendations and future steps, related to different aspects of the design of benchmarks, such as the selection and the characteristics of the datasets (quality, choice of pathogens and resistances, etc.), the evaluation criteria of the pipelines, and the way these resources should be deployed in the community.

Indexed as

Anti-Bacterial AgentsHigh-Throughput Nucleotide SequencingComputational BiologyDrug Resistance, BacterialAnti-Bacterial AgentsAntimicrobial resistancebenchmarkingbioinformaticsnext-generation sequencing

Identifiers

PMID35847383
PMCPMC9243550.2

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.